+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Hypertension Drug Market by Dosage Form, Age Group, Treatment Type, Distribution Channel, End User, Drug Class - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904908
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Hypertension Drug Market grew from USD 29.20 billion in 2024 to USD 31.83 billion in 2025. It is expected to continue growing at a CAGR of 8.76%, reaching USD 48.36 billion by 2030.

Navigating the Next Frontier in Hypertension Treatment

Hypertension persists as a leading global health challenge, affecting over one billion individuals and imposing substantial clinical and economic burdens on healthcare systems. Amid evolving therapeutic paradigms, the market for antihypertensive drugs is experiencing unprecedented change driven by innovation in pharmacology, shifting patient demographics, and heightened regulatory scrutiny. This executive summary offers a concise yet thorough exploration of the critical forces shaping the hypertension treatment landscape and outlines key considerations for stakeholders seeking to optimize their positioning.

Through a detailed examination of recent scientific breakthroughs, policy developments, and market dynamics, this report equips decision-makers with the insights needed to anticipate emerging trends and capitalize on growth opportunities. By tracing the trajectory of drug pipelines, distribution innovations, and competitive tactics, readers will gain a nuanced understanding of how to navigate a market defined by both complexity and potential. In an environment where patient outcomes hinge on timely access to effective therapies and where price pressures persist, informed strategic planning has never been more essential.

Emerging Transformations Redefining Hypertension Care

The hypertension market is undergoing transformative shifts as digital health integration, precision medicine, and patient-centric models converge to redefine treatment paradigms. Advances in genetic profiling and biomarker research are enabling clinicians to tailor antihypertensive regimens to individual risk profiles, moving beyond the traditional ‘‘one-size-fits-all’’ approach. Simultaneously, the emergence of remote patient monitoring platforms and telehealth services is improving adherence rates by facilitating real-time data exchange between patients and care teams.

On the regulatory front, expedited approval pathways for breakthrough designations are accelerating the introduction of novel mechanisms of action, while evolving pharmacovigilance requirements are ensuring safety standards remain rigorous. Market differentiation is now as much about digital companion tools and adherence support programs as it is about molecule efficacy. Meanwhile, increased competition from biosimilars and generics has intensified price sensitivity, encouraging manufacturers to pursue value-added formulations, extended-release options, and combination therapies that offer superior convenience and compliance. As a result, the competitive landscape is shifting towards versatile portfolios and strategic partnerships that blend scientific innovation with technological capabilities.

Unraveling the Effects of New US Tariffs on Drug Access

The implementation of new United States tariffs in 2025 has introduced a layer of complexity to pharmaceutical supply chains, directly influencing the cost structures of antihypertensive medications. Raw material sourcing, particularly for active pharmaceutical ingredients imported from select regions, now faces increased duties, prompting manufacturers to reassess procurement strategies. These tariff-related cost pressures have led some organizations to diversify suppliers, invest in domestic API production, and renegotiate long-term contracts to mitigate exposure.

In parallel, drug pricing negotiations with payers and distributors have been affected by the shifting cost base, driving collaborative efforts to identify efficiency gains in manufacturing and distribution. For products reliant on specialized injectable formulations, where production intricacies and sterility requirements compound expenses, companies are exploring localized fill-finish operations to reduce cross-border logistics. While the full extent of tariff impacts will evolve over time, the current landscape underscores the importance of agile supply chain management and proactive cost optimization to preserve market share and maintain patient access to critical hypertension therapies.

Deciphering Market Segments to Illuminate Growth Pathways

A deep dive into market segments reveals that the form in which an antihypertensive agent is delivered can significantly influence prescriber preference, patient acceptance, and cost considerations. Capsules offer preferred swallowability and dose flexibility for maintenance therapy, tablets drive high-volume demand through established manufacturing efficiencies, and injectables are essential for acute care scenarios and inpatient settings where rapid blood pressure control is paramount. When examining age cohorts, adult patients represent the core market, yet geriatric individuals exhibit a higher prevalence of comorbidities, necessitating careful polypharmacy management, whereas the pediatric segment demands tailored dosing accuracy and flavor-masked formulations to ensure adherence.

Treatment type segmentation highlights the sustained role of monotherapy for newly diagnosed or mild hypertension, while combination therapies-including dual therapy, fixed-dose combinations, and triple therapy-are gaining traction as the standard of care for resistant cases or patients with multiple cardiovascular risk factors. The distribution channel landscape illustrates that hospital pharmacies remain critical for specialized and intravenous regimens, online pharmacies are reshaping convenience and adherence through digital engagement, and retail pharmacies continue to serve as frontline access points for chronic medication refills. From an end user perspective, clinics drive early-stage diagnosis and therapy initiation, home care models facilitate long-term monitoring and patient empowerment, and hospitals manage complex interventions and acute episodes. Finally, drug classes such as ACE inhibitors maintain broad adoption for their proven efficacy and tolerability, ARBs attract prescriber interest for their favorable side-effect profile, beta blockers target patients with concurrent cardiac conditions, and calcium channel blockers along with diuretics fill strategic niches within combination regimens to optimize therapeutic outcomes.

Regional Dynamics Shaping Hypertension Therapy Uptake

Regional dynamics play a pivotal role in shaping market opportunity and competitive intensity within the hypertension drug arena. In the Americas, established healthcare infrastructures and mature reimbursement frameworks underpin strong demand for innovative therapies, while rising patient awareness and prevention programs bolster early diagnosis. Price sensitivities, however, drive a robust generics market that intensifies competition and compels branded manufacturers to highlight value propositions through patient support and outcome data.

Across Europe, the Middle East & Africa, a heterogeneous mix of developed and emerging markets creates both challenges and prospects. Regulatory harmonization within the European Union facilitates streamlined market entry, whereas country-specific pricing controls and reimbursement negotiations can prolong launch timelines. In emerging economies across Africa and the Middle East, the growing burden of cardiovascular disease coupled with expanding access to healthcare services signals untapped potential for both generics and differentiated therapies. The Asia-Pacific region is marked by rapid growth fueled by population size, increasing healthcare investments, and rising prevalence of hypertension. Local manufacturing capabilities are on the rise, and strategic collaborations with regional partners are accelerating the availability of advanced treatments. Policymakers’ focus on chronic disease management programs further amplifies market receptivity, positioning this region as a critical frontier for future expansion.

Leading Players Steering the Hypertension Market

The competitive landscape in the antihypertensive drug market is characterized by a blend of established pharmaceutical giants, specialized biotech firms, and emerging innovators. Leading organizations leverage extensive global distribution networks and robust R&D pipelines to sustain their market share, while agile players focus on niche opportunities and strategic collaborations to penetrate high-growth segments. Recent partnerships between established brands and digital health startups have resulted in integrated solutions that combine pharmacotherapy with remote monitoring, setting new standards for patient engagement.

Mergers and acquisitions remain prominent as companies seek to bolster their portfolios with complementary assets, ranging from novel molecular entities to proprietary delivery technologies. Simultaneously, alliances with contract manufacturing organizations support scale-up of high-volume products and enable faster time-to-market for innovative formulations. Companies are also investing in real-world evidence studies to demonstrate long-term value and secure favorable formulary placements. As a result, the marketplace is evolving into a dynamic ecosystem where scientific expertise, technological prowess, and strategic alliances converge to shape tomorrow’s standards of care.

Strategic Imperatives for Leaders in Hypertension Care

Industry leaders should prioritize the integration of digital health tools into their core offerings, embedding remote monitoring and adherence-enhancing technologies within product portfolios to differentiate in a crowded marketplace. Investing in combination therapies with optimized dosing regimens and fixed-dose formats can address the growing prevalence of resistant hypertension while simplifying treatment pathways for patients and providers alike. Strengthening supply chain resilience by diversifying API sources, localizing critical manufacturing steps, and forging strategic partnerships with logistics providers will mitigate the impacts of geopolitical shifts and tariff fluctuations.

Moreover, deploying real-world data analytics to support outcome-based contracting with payers can unlock new reimbursement models and reinforce the value proposition of premium therapies. Expanding presence in high-growth regions through joint ventures or licensing agreements will enable faster market entry and tailored strategies that reflect local regulatory and cultural landscapes. Finally, fostering collaborative research initiatives with academic institutions and health systems can accelerate the discovery of novel targets and biomarkers, ensuring a robust pipeline of next-generation antihypertensive solutions.

Rigorous Methodology Underpinning Our Market Insights

This research synthesizes insights from a rigorous methodology that combines primary and secondary data sources. Primary inputs include in-depth interviews with key opinion leaders, cardiologists, and endocrinologists, as well as discussions with supply chain experts and payers. Secondary research encompasses analysis of peer-reviewed journals, regulatory filings, clinical trial registries, and industry databases. Data triangulation ensures consistency across sources, while thematic coding facilitates identification of recurring trends and emerging signals.

Market segmentation analysis was conducted across dosage forms, age groups, treatment types, distribution channels, end users, and drug classes to uncover nuanced patterns of demand and competitive positioning. Regional assessments relied on country-level indicators, healthcare expenditure data, and policy reviews. Competitive benchmarking featured portfolio mapping, pipeline evaluation, and strategic partnership tracking. Throughout the process, rigorous validation sessions with industry veterans were held to corroborate findings and refine interpretations. The comprehensive yet focused scope of this study ensures that the resulting insights are both actionable and aligned with the real-world challenges faced by stakeholders in the hypertension sphere.

Summing Up the Hypertension Landscape and Future Outlook

The analysis presented in this executive summary underscores a market at the crossroads of innovation and complexity. Evolving regulatory landscapes, the emergence of precision medicine, and digital health integration are redefining how hypertension is managed, while external factors such as tariffs continue to influence cost structures and supply chains. Segmentation insights highlight the diverse needs of patients based on dosage preferences, age cohorts, treatment regimens, and distribution channels, and regional assessments reveal distinct opportunities and challenges across global markets.

Industry leaders that embrace strategic priorities-such as embedding technology into therapeutic offerings, securing supply chain flexibility, and leveraging data analytics-will be best positioned to capture value and drive superior patient outcomes. As the competitive battleground intensifies with new entrants and differentiated therapies, continuous monitoring of market shifts and proactive collaboration with clinical and regulatory stakeholders will be critical. By synthesizing these insights, this report lays a clear foundation for informed decision-making and underscores the pathways to sustainable growth in the dynamic world of hypertension therapeutics.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Dosage Form
    • Capsule
    • Injectable
    • Tablet
  • Age Group
    • Adult
    • Geriatric
    • Pediatric
  • Treatment Type
    • Combination Therapy
      • Dual Therapy
      • Fixed Dose Combination
      • Triple Therapy
    • Monotherapy
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Clinics
    • Home Care
    • Hospitals
  • Drug Class
    • Ace Inhibitors
    • Arbs
    • Beta Blockers
    • Calcium Channel Blockers
    • Diuretics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • Daiichi Sankyo Company, Limited
  • Teva Pharmaceutical Industries Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hypertension Drug Market, by Dosage Form
8.1. Introduction
8.2. Capsule
8.3. Injectable
8.4. Tablet
9. Hypertension Drug Market, by Age Group
9.1. Introduction
9.2. Adult
9.3. Geriatric
9.4. Pediatric
10. Hypertension Drug Market, by Treatment Type
10.1. Introduction
10.2. Combination Therapy
10.2.1. Dual Therapy
10.2.2. Fixed Dose Combination
10.2.3. Triple Therapy
10.3. Monotherapy
11. Hypertension Drug Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Hypertension Drug Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
13. Hypertension Drug Market, by Drug Class
13.1. Introduction
13.2. Ace Inhibitors
13.3. Arbs
13.4. Beta Blockers
13.5. Calcium Channel Blockers
13.6. Diuretics
14. Americas Hypertension Drug Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Hypertension Drug Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Hypertension Drug Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Novartis AG
17.3.2. Pfizer Inc.
17.3.3. Sanofi S.A.
17.3.4. Merck & Co., Inc.
17.3.5. AstraZeneca PLC
17.3.6. Boehringer Ingelheim International GmbH
17.3.7. Bayer AG
17.3.8. Takeda Pharmaceutical Company Limited
17.3.9. Daiichi Sankyo Company, Limited
17.3.10. Teva Pharmaceutical Industries Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. HYPERTENSION DRUG MARKET MULTI-CURRENCY
FIGURE 2. HYPERTENSION DRUG MARKET MULTI-LANGUAGE
FIGURE 3. HYPERTENSION DRUG MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL HYPERTENSION DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. HYPERTENSION DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. HYPERTENSION DRUG MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. HYPERTENSION DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HYPERTENSION DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DUAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY FIXED DOSE COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY TRIPLE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ARBS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 51. CANADA HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 52. CANADA HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 53. CANADA HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 54. CANADA HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 55. CANADA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. CANADA HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. CANADA HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. MEXICO HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 59. MEXICO HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 60. MEXICO HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 62. MEXICO HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. MEXICO HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. MEXICO HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. GERMANY HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 95. GERMANY HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 96. GERMANY HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 97. GERMANY HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 98. GERMANY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. GERMANY HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. GERMANY HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. FRANCE HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 102. FRANCE HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 103. FRANCE HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 104. FRANCE HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 105. FRANCE HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. FRANCE HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. FRANCE HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 112. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. RUSSIA HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 115. ITALY HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 116. ITALY HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 117. ITALY HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 118. ITALY HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 119. ITALY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. ITALY HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. ITALY HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. SPAIN HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 123. SPAIN HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 124. SPAIN HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 125. SPAIN HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 126. SPAIN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. SPAIN HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. SPAIN HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 133. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 140. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 147. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. DENMARK HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 151. DENMARK HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 152. DENMARK HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 153. DENMARK HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 154. DENMARK HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. DENMARK HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. DENMARK HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. QATAR HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 165. QATAR HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 166. QATAR HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 167. QATAR HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 168. QATAR HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. QATAR HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. QATAR HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. FINLAND HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 172. FINLAND HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 173. FINLAND HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 174. FINLAND HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 175. FINLAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. FINLAND HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. FINLAND HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. SWEDEN HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 189. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. NIGERIA HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. EGYPT HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 193. EGYPT HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 194. EGYPT HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 195. EGYPT HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 196. EGYPT HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. EGYPT HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. EGYPT HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. TURKEY HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 200. TURKEY HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 201. TURKEY HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 202. TURKEY HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 203. TURKEY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. TURKEY HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. TURKEY HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 213. NORWAY HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 214. NORWAY HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 215. NORWAY HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 216. NORWAY HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 217. NORWAY HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. NORWAY HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. NORWAY HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 220. POLAND HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 221. POLAND HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 222. POLAND HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 223. POLAND HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 224. POLAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. POLAND HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. POLAND HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 231. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. SWITZERLAND HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 242. CHINA HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 243. CHINA HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 244. CHINA HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 245. CHINA HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 246. CHINA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. CHINA HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. CHINA HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 249. INDIA HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 250. INDIA HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 251. INDIA HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 252. INDIA HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 253. INDIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. INDIA HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. INDIA HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 256. JAPAN HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 257. JAPAN HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 258. JAPAN HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 259. JAPAN HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 260. JAPAN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. JAPAN HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. JAPAN HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. INDONESIA HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 284. THAILAND HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 285. THAILAND HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 286. THAILAND HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 287. THAILAND HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 288. THAILAND HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. THAILAND HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. THAILAND HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. MALAYSIA HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 305. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 306. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 307. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 308. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 309. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. SINGAPORE HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 312. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 313. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 314. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 315. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 316. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. VIETNAM HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 319. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 320. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 321. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 322. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 323. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 324. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 325. TAIWAN HYPERTENSION DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 326. HYPERTENSION DRUG MARKET SHARE, BY KEY PLAYER, 2024
TABLE 327. HYPERTENSION DRUG MARKET, FPNV POSITIONING MATRIX, 2024

Companies Mentioned

The companies profiled in this Hypertension Drug market report include:
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • Daiichi Sankyo Company, Limited
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information